Effect of lead on electrophoretic mobility of rat erythrocytes

Lead often affects the erythrocyte membrane. The relationship between the changes in erythrocyte membrane and the anemia caused by lead is still unclear. Initially, the effect of lead injected intraperitoneally on the electrophoretic mobility of rat erythrocytes was investigated in order to study the relationship between them. As indices of lead exposure, hemoglobin (Hb) levels, hematocrits (Ht), δ-aminolevulinic acid dehydratase (ALA-D) activities and blood lead (blood Pb) levels in the injected rats were also examined. Exposure to lead significantly decreased the mobility of rat erythrocytes. The changes in mobility seemed to be less sensitive than those in ALA-D activity, however, the decreases in mobility were simultaneous with or prior to those in Hb level and Ht. The decreases in mobility were evident to some extent below a blood Pb level of 100 μg/100 ml and generally present at a level of 100 μg/100 ml and over. In the rats exposed to lead a significant negative correlation was found between the mobilities and the logarithms of blood Pb level.     

自体脾静脉移植在门静脉和肠系膜上静脉联合切除的胰十二指肠切除术中的应用

目的：探讨以自体脾静脉重建门静脉系统在联合PV/SMV切除的胰十二指肠切除术中临床应用的可行性。方法：回顾性分析3例胰头癌病人在胰十二指肠切除术中采用脾静脉替代门静脉系移植的应用及其效果。结果：手术均顺利,门静脉阻断时间分别为52min、38min和30min。术后B超随访无脾肿大、腹水等情况,门静脉流量均正常（分别为1450ml/min、1200ml/min和1500ml/min）,术后CTA复查显示重建的血管血流通畅,无血栓形成或狭窄,术后生活质量得到明显改善,黄疸消失,肝功能正常,均痊愈出院。结论：在联合PV/SMV切除的胰十二指肠切除术中采用自体脾静脉替代门静脉系的移植是可行的。     

地塞米松对扩张皮瓣血运障碍的救治

目的寻求扩张皮肤Ⅱ期手术形成皮瓣时出现血运障碍及防止坏死的有效治疗方法。方法皮瓣出现血运障碍时，立即静脉给予地塞米松0．4mg／kg，然后逐渐减量，术后6d停药。10d时观察判断皮瓣成活情况。结果35例出现血运障碍的皮瓣，经救治完全成活33例，大部分成活2例。成活后皮瓣色泽、弹性均好。结论及时用地塞米松是防止扩张皮瓣出现血运障碍及坏死的良好方法。     

原发性肝癌凝血功能变化的临床价值

目的 :探讨原发性肝癌患者凝血功能变化情况及其临床价值。方法 :对原发性肝癌 6 0例进行凝血酶原时间 (PT)、活化部分凝血酶原时间 (APTT)、纤维蛋白原 (FIB)、凝血酶时间 (TT) 4项凝血指标进行检测和对比分析。结果 :原发性肝癌组与对照组相比 ,PT、APTT、TT均显著延长 P<0 .0 1,FIB明显降低 P<0 .0 5 ,肝癌并发症组与无并发症组相比 ,PT、APTT均显著延长 P<0 .0 1,P<0 .0 5 ,FIB显著降低 P<0 .0 1;原发性肝癌转移组与无转移组相比 ,PT、APTT明显延长 P<0 .0 5 ,FIB显著降低 P<0 .0 5。不同肝功能分级检测结果显示 PT、APTT和 FIB有显著差别。结论 :原发性肝癌患者可出现凝血功能障碍 ,而凝血功能变化情况对评估肝癌肝损害的程度、监测病情变化 ,指导临床治疗及其预后具有一定的应用价值。     

常用生理参数的测量原理

随着医学事业的发展,监护仪得到广泛的运用,就医用监护仪常用生理参数的工作原理简述如下。     

去除白细胞输血的临床意义

目的:评估去除白细胞输血的临床应用价值。方法:251例患者接受了去除白细胞红细胞悬液761U,(每人1￣8U不等),对其中200U红细胞悬液滤除白细胞前、后分别进行白细胞计数和血红蛋白测定,并对其输血反应进行了观察。结果:发现应用白细胞滤器后,其白细胞数比过滤前显著减低,过滤前、后白细胞数分别为(6.16±1.44)×109/L与(0.12±0.10)×109/L(P<0.01),血红蛋白过滤前、后无显著性差异,分别为:(161.58±23.31)g/L与(157.84±22.35)g/L,P>0.05。251例接受去白细胞受血者均未出现输血反应。结论:白细胞滤器能有效去除白细胞,去除白细胞能减少非溶血性输血反应。     

脊柱化脓性骨髓炎的诊断及治疗

目的探讨脊柱化脓性骨髓炎的诊断及治疗方法.方法1999年7月～2003年8月,收治以腰痛伴发热为主要临床表现的患者12例,男7例,女5例;年龄13～61岁,平均36.6岁.患者先有胸、腰背部疼痛,11例出现剧烈疼痛,伴有体温升高(超过39℃),局部无红肿,有深压痛及叩击痛,脊柱活动受限,但无脊髓及马尾神经压迫症状,二便正常.对患者行白细胞计数、血沉和MR等检查.12例患者中,10例血沉超过60 mm/1 h,1例血沉为28mm/1 h,1例血沉为50mm/1 h.2例患者白细胞计数超过1.0×109/L.4例患者经椎弓根穿刺活检,阳性率为75%.入院后即给予静脉滴注抗生素治疗至少6周,继而口服抗生素治疗6周,11例患者血沉于治疗后1个月下降50%以上,约91.7%的患者保守治疗有效.结果12例患者9例获得随访,随访时间6个月～4年,平均2年2个月.获得随访的9例患者中,7例无临床症状,1例有轻微背痛,1例有慢性严重背痛的患者,经保守治疗无效后,行手术治疗;7例行MR检查,2例显示局部椎体及椎间盘仍有破坏,T1加权像示低信号范围缩小,T2加权像示仍为高信号,但无腰背痛等临床症状.结论脊柱化脓性骨髓炎患者血沉较白细胞计数敏感;MR及病理检查对明确诊断有重要意义.采用静脉滴注抗生素及口服抗生素序贯疗法治疗1个月后血沉下降是保守治疗成功的标志,保守治疗无效者可手术治疗.     

脑梗死急性期降压治疗对预后的影响

目的 研究脑梗死急性期降压及在不同时间进行降压治疗对患者近期预后的影响.方法 据发病后是否降压及进行降压的时间,将198例急性脑梗死患者分为6组,观察各组患者神经功能缺损程度及心脑血管事件的再发生率和病死率.结果 在发病后进行降压治疗的患者中其心脑血管事件再发率和病死率明显低于未降压组（P＜0.01） 3d后降压组患者神经功能恢复的程度明显好于未降压组（P＜0.01）.结论 降压治疗可以降低患者心脑血管事件的发生率和病死率3d后进行降压治疗的患者神经功能恢复明显要好.     

Clinical efficacy, safety and pharmacokinetic properties of the factor VIII concentrate Haemoctin® SDH in previously treated patients with severe haemophilia A

Clinical efficacy, safety and pharmacokinetic properties of the high-purity double-virus inactivated plasma-derived factor VIII concentrate Haemoctin SDH (pdFVIII) were evaluated in three prospective open-label uncontrolled studies in previously treated patients (PTPs) with severe haemophilia A. The pharmacokinetic properties assessed at baseline and after 3 months of treatment are in accurate accordance with published data and remain unchanged over time (study A, n = 12). Mean terminal elimination half-life was 11.8 and 11.9 h, mean incremental recovery (IU dL(-1)/IU kg(-1)) was 2.3 and 2.0, respectively. Long-term efficacy and safety, in particular the potential immunogenicity, were investigated in a total of 53 PTPs (studies A and B) treated prophylactically and on-demand, as required. PdFVIII has shown to be effective in preventing and controlling bleeding episodes; 23.5% of patients were free of bleeding events. A total of 177 haemorrhages occurred with 74.0% resolving after a single infusion, 87.6% within two infusions. 98.3% of responses reported on haemorrhages were rated as 'excellent' or 'good'. Moreover, 'excellent' haemostatic efficacy has been demonstrated in 10 surgical procedures including general and severe orthopaedic interventions (study C). No complication occurred in any surgery. Few adverse events were reported, one patient developed a high-titre FVIII inhibitor without clinical relevance. In all three studies, over 6 million units were administered in nearly 4300 infusions, approximately 94% units or infusions were given for prophylaxis and only 6% for treatment on-demand. In conclusion, pdFVIII has shown to be effective, safe and well tolerated in long-term prophylaxis and treatment on-demand as well as after minor and major surgical procedures.